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Abstract
Background: Screening for antinuclear antibodies by 
indirect immunofluorescence (ANA-IIF) is essential in 
the diagnostic workup of ANA-associated autoimmune 
rheumatic diseases (AARDs). However, also healthy indi-
viduals may test positive, making the interpretation chal-
lenging. Recent reports suggest that dense fine speckled 
70 antibodies (anti-DFS70) may facilitate this challenge. 
Here, we investigate their clinical importance based on 
data from four Belgian laboratories (one primary, two sec-
ondary and one tertiary care).
Methods: At least one specific DFS70 assay (DFS70 IgG 
ELISA or lineblot [Euroimmun, full length antigen] and/
or DFS70 IgG CLIA [Inova Diagnostics, truncated antigen]) 
was performed on four consecutive cohorts of homogene-
ous-like ANA-IIF samples (n = 697). Co-occurrence with 
AARD-specific ANA and clinical information were docu-
mented in the anti-DFS70-positive samples.
Results: Using a combination of solid phase techniques, 
we found between 7.6% and 26% anti-DFS70 in the 
different cohorts. Focusing on anti-DFS70 CLIA-positive 
samples without co-occurrence of AARD-specific ANA, we 
observed a trend towards lower frequency in tertiary (8% 
[p = 0.0786]) and secondary care (12% [p = 0.1275] and 6% 
[p < 0.001]) compared to primary care (21%). Moreover, 
in this specific subpopulation, AARD was less frequent 
(0%–50% compared to 6%–77% in the total anti-DFS70-
positive group).
Conclusions: Anti-DFS70 prevalence depends on the 
applied assay and care setting. Our data suggest that, for 
an ANA-IIF-positive patient, it is rather the absence of 
AARD-associated ANA and clinical symptoms that con-
tribute to the exclusion of AARD than the presence of anti-
DFS70. Nevertheless, isolated anti-DFS70 helps to clarify 
positive ANA-IIF results, especially if pretest probability 
for AARD is low.
Keywords: anti-DFS70/LEDGF; antinuclear antibodies; 
systemic rheumatic autoimmune diseases.
Introduction
Antinuclear antibody (ANA) detection is considered 
essential in the diagnostic workup of ANA-associated 
autoimmune rheumatic diseases (AARDs) [1, 2]. In the 
routine laboratory, indirect immunofluorescence (IIF) 
on HEp-2(000) cells is the most widely applied screening 
method [3]. However, because screening for ANA by indi-
rect immunofluorescence (ANA-IIF) lacks specificity with 
up to 20% positivity found in apparently healthy individu-
als, further testing to identify the specific antigenic targets 
of ANA is essential to improve the diagnostic contribution 
of the positive ANA-IIF test result [4].
Clinicians may have different reasons for requesting 
ANA tests. ANA results can be used to support or to assist 
the clinical diagnosis in patients with symptoms of AARD. 
In addition, in some AARD (e.g. systemic sclerosis), the 
presence of specific ANA is also associated with particular 
disease manifestations emphasizing their use as prognos-
tic markers [5]. However, in daily clinical practice, an evo-
lution in the request pattern is observed with ANA tests 
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more frequently ordered in a wider clinical framework. 
In this context with low pretest probability, a negative 
ANA-IIF test may contribute to exclude some AARDs like 
systemic lupus erythematosus, mixed connective tissue 
disease and systemic sclerosis [4]. Nevertheless, this 
approach also results in a higher frequency of ‘clinically 
out of context’ ANA-IIF positivity, leading to unnecessary 
follow-up testing, possible misdiagnosis and even incor-
rect therapies [1]. Recent observations suggest that iso-
lated DFS70 antibodies (anti-DFS70) might contribute to 
explaining a significant proportion of these AARD-unre-
lated ANA-IIF-positive results [6].
Anti-DFS70 target the lens epithelium-derived growth 
factor (LEDGF) and react with a conserved and conforma-
tional epitope, restricted to a single region located within 
the integrase binding domain at the C-terminal of the 
protein [7]. On ANA-IIF, anti-DFS70 are characterized by 
a dense fine speckled (DFS) staining of the nucleoplasm 
of the interphase cells, typically excluding the nucleoli, 
and by a strong granular-speckled staining of the con-
densed mitotic chromosomes (for reference images, see 
website of ICAP [International consensus on Antinuclear 
Antibody Pattern, http://www.anapatterns.org], pattern 
AC-2) [8, 9].
Anti-DFS70/LEDGF were first described in 1994 in 
interstitial cystitis and later on in a variety of other non-
autoimmune conditions (e.g. atopic dermatitis, asthma, 
gynecologic syndromes and neoplasia), autoimmune con-
ditions (e.g. autoimmune thyroiditis and AARD such as 
Sjögren’s syndrome and systemic lupus erythematosus) 
and even healthy donors [7, 10–16].
Several studies observed higher frequencies of anti-
DFS70 in healthy individuals compared to AARD [2, 12, 15, 
17, 18]. In a recent meta-analysis of five studies, a mean 
prevalence of 7.8% ± 6.2% (median 7.6%) anti-DFS70 in 
healthy controls was calculated, regardless the detection 
method used. In the same study, the calculated mean 
prevalence of anti-DFS70 in AARD was 4.5 ± 2.8% (median 
3.9%), with isolated anti-DFS70 reactivity being extremely 
rare (0.7 ± 0.9% [median 0.45%]) [7]. Based on these find-
ings, some authors suggested that isolated anti-DFS70 
positivity could be used to exclude the diagnosis of AARD 
[2, 7]. By contrast, for other authors, this proposal is dif-
ficult to support as the ANA test is usually not requested 
in healthy individuals, resulting in a substantial part of 
the anti-DFS70-positive tests in patients with AARD [19]. 
Their idea was also supported by the limited data avail-
able on unselected sera for which routine ANA screening 
was requested, showing low prevalence of confirmed anti-
DFS70 (1.7% ± 0.1% [median 1.7%]), approaching the situ-
ation observed in AARD [2, 7].
Various other factors contribute to the controversy 
on the true clinical significance of anti-DFS70. First, 
differences in frequencies of anti-DFS70 are observed 
depending on the detection technique (ANA-IIF, 
enzyme-linked sorbent immunoassay [ELISA], chemilu-
minescence immunoassay [CLIA] or immunoblot) used. 
For instance, Bizzaro and coworkers demonstrated that 
only 14% of their initial DFS-ANA-IIF-positive sera, 
were positive on the DFS70 ELISA. In addition, they 
also observed important HEp-2 cell line variability [19]. 
Second, differences between the solid phase assays 
were also described, probably related to the differences 
in antigens used [20]. Third, it is to be expected that the 
true added value of anti-DFS70 detection in a routine 
context is also dependent on the request pattern and the 
setting of the laboratory (primary care versus secondary 
or tertiary care). Based on the idea that anti-DFS70 are 
more frequent in healthy and that isolated anti-DFS70 
are rare in AARD, it is to be expected that in popula-
tions with higher pretest probability of AARD, the preva-
lence of anti-DFS70 is lower and the co-occurrence of 
anti-DFS70 with other AARD-associated ANA is higher, 
resulting in lower clinical added value. However, no 
formal studies have been performed to document this 
assumption.
The purpose of this multicenter study was to evalu-
ate the added value of detecting anti-DFS70 in different 
routine contexts. Therefore, we pooled data from four 
Belgian laboratories in different care settings and com-
pared the frequency and co-occurrence of anti-DFS70 with 
other AARD-associated ANA. Also demographics and clin-
ical data were collected.
Materials and methods
Samples
Consecutive samples of adult patients (≥18 years) for which ANA-IIF 
was requested were included in this study. Samples originated from 
four Belgian clinical routine laboratories in different care settings: 
Algemeen Medisch Laboratorium Antwerp (AML) (primary care), 
OLV Hospital Aalst (OLVA) (secondary care), GZA Hospitals Antwerp 
(GZA) (secondary care) and University Hospital Ghent (UZG) (tertiary 
care). The number of samples included and the collection timeframe 
in each center are shown in Table 1. As the recognition of the DFS70-
ANA-IIF pattern is difficult, definite inclusion for further anti-DFS70 
analysis was based on the presence of a homogeneous ANA IIF pat-
tern (i.e. homogeneous and regular fluorescence of the interphase 
nuclei and metaphase chromatin) or a speckled mitosis-positive ANA 
IIF pattern (i.e. all types of speckled fluorescence of interphase nuclei 
in combination with a speckled aspect of the metaphase chromatin), 
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further referred to as the homogeneous-like group. All serum sam-
ples were obtained as part of routine screening for ANA. No informed 
consent was needed for this retrospective study, but the study was 
performed according to the Declaration of Helsinki and approved by 
the Local Hospital Ethics Committee.
Routine ANA-IIF analysis and confirmatory tests
All samples were tested for ANA-IIF, double-stranded DNA  antibodies 
(anti-dsDNA) and extractable nuclear antibodies (anti-ENA) using 
the routine method in each center. See Table 1 for more details on 
the methods used. For ANA-IIF analysis, three centers used HEp-2, 
and one center used HEp-2000. For the detection of anti-ENA, three 
centers used a screening method with pooled antigens before further 
identification of the specific reactivities. As the screening dilution 
for ANA-IIF routine analysis differed between centers, the data were 
aligned towards a cutoff for positivity of 1:160.
Detection of DFS70 antibodies
Three different techniques for the detection of anti-DFS70  were 
used in this study: one enzyme-linked immunosorbent assay (Anti-
DFS70 ELISA, EUROIMMUN AG, Lübeck, Germany) (DFS70 ELISA), 
one lineblot (Euroline ANA Profile 3 plus DFS70, EUROIMMUN AG, 
Lübeck, Germany) (DFS70 LB) and one chemiluminescence immu-
noassay (QUANTA Flash® DFS70, Inova diagnostics, San Diego, CA, 
USA) (DFS70 CLIA). The DFS70 ELISA and LB methods use the full-
length (FL) protein (aa 1-530), and the DFS70 CLIA method uses a 
truncated (TC) antigen (aa 349–435). For all assays, the manufactur-
ers’ cutoff was applied. In three centers (GZA, OLVA and UZG) DFS70 
antibodies were detected using two different solid phase techniques 
(see Table 1). In the primary care center (AML), only one technique 
was used (DFS70 ELISA or CLIA depending on the timeframe). All 
DFS70-positive samples (positivity with at least one technique) from 
the secondary and tertiary care centers were also analyzed with an 
immunoabsorption method (NOVA Lite® HEp-2 Select, Inova diag-
nostics, San Diego, CA, USA).
Data analysis
All data evaluations were performed using MedCalc® Software ver-
sion 15.6.1 (Ostend, Belgium). The Mann-Whitney test was used to 
evaluate the difference between two independent samples. For com-
parison of proportions, χ2-testing with Yates’ correction for continu-
ity was applied. A statistical significance level of 0.05 was used. In 
case of multiple testing, the Bonferroni correction was applied.
Results
Description of the referral pattern
The demographics of each population and characteris-
tics of the referral pattern per center are given in Table 2. 
Higher numbers of referrals from rheumatologists were 
observed in secondary and tertiary care compared to 
primary care.
ANA-IIF positivity and frequency of the 
 homogeneous-like pattern in the different 
cohorts
The highest ANA-IIF positivity in routine was observed 
in the UZG (58%) and the OLVA (52%), whereas lower 
frequencies were observed in AML (23%) and GZA (18%). 
However, it must be mentioned that UZG applies a lower 
screening serum dilution (1:40) compared to OLVA (1:80), 
AML (1:80) and GZA (1:160). At identical cutoff of 1:160, a 
total of 694 samples showed a homogeneous-like pattern 
on ANA-IIF. The frequency of this pattern within each indi-
vidual consecutive cohort was 3% (n = 327/11018) for AML, 
8% (n = 50/622) for UZG, 9% (n = 138/1481) for GZA and 
19% for OLVA (n = 211/1109).
Differences between solid phase assays for 
anti-DFS70 detection
In three centers (GZA, OLVA and UZG, n = 367), DFS70 anti-
bodies were detected using two different solid phase tech-
niques (see Table 1): one technique using the TC antigen 
(DFS70 CLIA) and one technique using the FL antigen 
(DFS70 ELISA or LB). Overall, a kappa agreement of 0.749 
(95% confidence interval [CI] 0.659–0.859) between the 
FL and TC antigen-based assays was observed. In total, 
49 (13%) of 367 samples showed reactivity in at least 
one assay, 63% (n = 31/49) of them being positive in both 
assays. Most single positive samples (n = 17/18) showed 
reactivity in an FL antigen assay (DFS70 ELISA or LB).
Table 2: Description of the consecutive sample cohorts and characteristics of the referral pattern per center.
AML (n = 11018) GZA (n = 1481) OLVA (n = 1109) UZG (n = 622)
Median age (range) 51 year (18–101) 54 year (18–95) 53 year (18–95) 50 year (18–89)
Male/female (female%) 3479/7539 (68.4%) 530/951 (64.2%) 344/765 (69.0%) 195/427 (68.6%)
% Requests from rheumatologists 5% 26% 55% 31%
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Frequency of anti-DFS70 in the different 
cohorts
In total, 134 of 694  homogeneous-like samples were 
found positive for anti-DFS70 using a combination of 
the solid phase techniques. See Table 3 for an overview 
of the positive samples in each center in relation to the 
different assays. When only anti-DFS70 reactivity on CLIA 
(55 samples in total) was taken into account to calculate 
the frequencies over the different cohorts, the highest 
frequency of anti-DFS70  within the homogeneous-like 
population was observed in AML (23%, n = 23/101), with a 
trend towards lower frequency in tertiary care (UZG, 10%, 
n = 5/50) and secondary care (GZA [13%, n = 14/106], OLVA 
[6%, n = 13/211]). Nevertheless, significance could only be 
shown for OLVA (p < 0.001).
Co-occurrence of anti-DFS70 with other ANA
Co-occurrence of anti-DFS70 with other AARD-associated 
ANA as determined by the routine methods was observed 
in 9% (n = 5) of the 55 DFS70 CLIA-positive samples (see 
Table 3 for individual numbers of the centers). Higher 
frequencies of co-occurrence were found in the FL assay 
(DFS70 LB or ELISA) positive samples (31%, n = 15/48 [only 
tertiary and secondary care taken into account]), with up 
to 71% (n = 12/17) co-occurrence in the positive samples 
without concurrent CLIA reactivity (single FL assay posi-
tivity, p < 0.0001).
The frequency of DFS70 CLIA reactivity without 
concomitant routinely detected AARD-associated ANA 
ranged between 6% and 21%, with a trend towards 
lower frequency in tertiary care (UZG 8%, n = 4/50) 
and secondary care (GZA [12%, n = 13/106], OLVA 
[6%, n = 12/211]) compared to primary care (AML 21%, 
n = 21/101). However, only the comparison between 
OLVA and AML was found to be statistically significant 
(p < 0.001).
All DFS70-positive samples originating from the sec-
ondary and tertiary care centers were also analyzed with 
the NOVA Lite® HEp-2 Select immunoabsorption method 
to determine isolated anti-DFS70 reactivity on IIF. Using 
this approach, 78% (n = 25/32) of the DFS70 CLIA positive 
samples showed a pattern suggestive for isolated anti-
DFS70 IIF reactivity. By contrast, all samples with single 
FL assay reactivity (n = 17) had an ANA-IIF pattern on 
HEp-2 Select suggestive of the co-occurrence of other ANA 
reactivities, and in 64% (n = 11) of them, the specific reac-
tivity was also identified in the routine anti-ENA/dsDNA 
methods. The most frequently observed reactivity was 
anti-Scl70 (in 7/17 [41%]). Other reactivities were anti-Sm 
(n = 2), anti-Ro52 (n = 4), anti-Ro60 (n = 3), anti-SSB (n = 1) 
and anti-dsDNA (n = 1).
Table 3: Numbers of samples showing the homogeneous-like pattern and DFS70 reactivity over the different cohorts and in relation to the 
different solid phase techniques.
Number of samples   Total  AML   GZA  OLVA  UZG
Homogeneous-like samples   694  327a   106b  211  50
Anti-DFS70-positive samples based on positivity with 
at least 1 technique [% of homogeneous-like samples]
  134 [19%]  85a [26%]   20 [19%]  16 [7.6%]  13 [26%]
Anti-DFS70-positive samples in relation to the applied 
technique
         
 – CLIA+   55  23   14c  13c  5c
 – FL assay+   110  62   19  16  13
 – Single CLIA+   1e  NAd   1  0  0
 – Single FL assay+   17e  NAd   6  3  8
Anti-DFS70-positive samples without concurrent ANA-
reactivity in relation to the applied techniquef
         
 – CLIA+   50  21   13  12  4
 – FL assay+   91  58   15  13  5
 – Single CLIA+   1e  NA   1  0  0
 – Single FL assay+   5e  NA   3  1  1
CLIA, chemiluminescence immunoassay using the truncated antigen; FL assay, lineblot or enzyme-linked sorbent assay using the full-length 
antigen; NA, not applicable. aOne hundred and one samples were analyzed with CLIA of which 23 samples were positive on DFS70 CLIA; 
226 samples were analyzed with ELISA of which 62 were found positive. bThirty-two samples were excluded because of sample short-
age or double inclusion in the consecutive series. cAll (except 1 GZA sample) showed double reactivity for CLIA and a full-length antigen-
based assay (lineblot or ELISA). dSamples were analyzed by either CLIA or ELISA. eOnly data from secondary and tertiary care centers were 
included.  fDefinition of concurrent ANA reactivity based on the routine anti-ENA/dsDNA tests.
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Demographic and clinical characterization of 
the anti-DFS70-positive samples
We evaluated the characteristics of the isolated anti-
DFS70  CLIA-positive samples (comparison of isolated 
DFS70+ versus isolated DFS70−). The results are sum-
marized in Table 4. A female dominance in the isolated 
anti-DFS70-positive cohorts was observed for three out 
of the four centers without significant difference. For 
two centers, the isolated anti-DFS70-positive patient 
group was significantly younger than the negative group. 
No  significant differences in the proportion of ANA-IIF 
titers ≥1/160 were observed.
We also documented the association with AARD in 
the anti-DFS70-positive samples of three cohorts (UZG, 
GZA and OLVA) (Table 5) by retrospective review of the 
medical records and laboratory data. Considering all 
DFS70-positive samples (at least one method DFS70 posi-
tive), the highest association between AARD and anti-
DFS70 positivity was observed in UZG (77%, n = 10/13). A 
lower frequency of AARD was observed in the secondary 
care centers (25% [n = 5/20, GZA] and 6% [n = 1/16, OLVA]). 
Table 4: Characteristics of the isolated anti-DFS70 CLIA-positive samples.
Number of samples   AML   GZA   OLVA   UZG
Number of isolated anti-DFS70 CLIA+ 
samples within the homogeneous-like cohort
  21/101a,b   13/106a   12/211a   4/50a
Female, %
 Isolated DFS70+   76%   82%   80%   100%
 Isolated DFS70−   89%   76%   75%   83%
 p-Value (χ2)   p = 0.2595   p = 0.9373   p = 0.9923   p = 0.8422
Age (median, [range])
 Isolated DFS70+   41 [25–83]   41 [21–82]   46 [20–76]   51[28–56]
 Isolated DFS70−   59 [19–91]   57 [22–88]   57 [24–91]   51 [19–86]
 p-Value (Mann-Whitney)c   p = 0.00005   p = 0.2612   p = 0.0253   p = 0.6041
ANA-IIF titer (% with titer ≤1/160)
 Isolated DFS70+   81%   54%   25%   NP
 Isolated DFS70−   68%   37%   36%   NP
 p-Value (χ2)   p = 0.0924   p = 0.2404   p = 0.4469  
CLIA, chemiluminescence immunoassay; NP, not performed. aDefinition of isolated reactivity based on the anti-dsDNA and anti-ENA routine 
assays. bFor AML, only samples performed on CLIA (n = 101) were taken into account. cSignificant difference shown in bold.
Table 5: SARD association in anti-DFS70-positive samples.
  GZA   OLVZ   UZG
Anti-DFS70-positive samples 
(positivity with at least one technique)
     
 Number   20   16   13
 n SARD+   5   1   10
 % SARD+   25%   6%   77%
 Type SARDa   SLE (n = 5)   SSc (n = 1)  SLE (n = 1), SSc (n = 9)
Anti-DFS70 CLIA+
 Number   14   13   5
 n SARD+   1/13b   0/13   3/5
 % SARD+   8%   0%   60%
 Type SARDa   SLE (n = 1)     SLE (n = 1), SSc (n = 2)
Isolated anti-DFS70 CLIA+b
 Number   11   10   4
 n SARD+   0/10c   0/10   2/4
 % SARD+   0%   0%   50% SARD
 Type SARDa       SLE (1), SSc (1)
SLE, systemic lupus erythematosus; SSc, systemic sclerosis. aAssociation with SARD documented based on retrospective review of the 
medical records and laboratory data. bDefinition of isolated reactivity based on the Hep-2 Select assay. cNo clinical data available for  
1 anti-DFS70-positive patient.
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Focusing on the isolated anti-DFS70 CLIA-positive samples 
defined using HEp-2 select analysis, the association with 
AARD was lower (50% in UZG, n = 2/4) and absent in the 
secondary care centers.
Strategy for routine analysis
We also evaluated the possible routine impact of detect-
ing DFS70 antibodies on every homogeneous-like sample 
without concomitant AARD-associated ANA. We calcu-
lated that extra anti-DFS70 testing would be necessary in 
16% of the 1109 consecutive samples in OLVA (173 samples 
showed a homogeneous-like pattern on IIF with no 
AARD-associated ANA in the routine tests), in 5% for 
UZG (n = 30/622), in 4% for GZA (n = 62/1481) and in 2% 
for AML (n = 91/4180, consecutive samples analyzed from 
December 2015 to April 2016). The chances of finding anti-
DFS70 in these samples eligible for testing were 21% (GZA, 
n = 13/62), 13% (UZG, n = 4/30), 7% (OLVZA, n = 12/173) and 
23% (n = 21/91) for AML. The frequencies of isolated anti-
DFS70  within the homogeneous-like cohorts (UZG 8%, 
GZA 12%, OLVA 6% and AML 21% – see above) match the 
estimated decrease in anti-ENA/dsDNA testing based on 
the assumption that no testing will be performed during 
follow-up in case of isolated anti-DFS70 positivity.
Discussion
Today, it is accepted that screening for ANA by IIF remains 
indispensable in the differential diagnosis of AARD [3]. In 
addition, ANA-IIF analysis is, more frequently than before, 
ordered in a wider clinical framework, resulting in lower 
pretest probability of AARD. Against this background of a 
less focused request pattern, several authors reported the 
presence of anti-DFS70 antibodies (1%–15%) in patients 
referred for ANA testing [2, 21–26]. In our study on differ-
ent consecutive populations referred for ANA testing, we 
detected 0.5% anti-DFS-70 using CLIA in primary care, 
0.9%–1.2% in secondary care and 0.9% in tertiary care. 
Therefore, we cannot confirm the suggestion of Seelig 
and colleagues that a lower prevalence of DFS-70 antibod-
ies is to be expected with higher quota of AARD patients 
within the clientele [7]. Nevertheless, we observed a trend 
towards lower frequency of anti-DFS70 within the homo-
geneous-like samples on ANA–IIF in tertiary care (10%) 
and secondary care (13% and 6%) compared to primary 
care (23%). Previous findings showing that anti-DFS70 
were more frequent in younger patients were confirmed in 
three out of four cohorts. By contrast, significance could 
not be shown for the previously reported higher frequency 
of females [15, 17].
The laboratory identification of anti-DFS70 has some 
important challenges. Indeed, differences in frequency 
of anti-DFS70 are observed depending on the detection 
technique used, and even within methods, variability is 
observed [17, 19, 20]. For ANA-IIF, the differences have 
been assigned to the subjectivity of the interpretation as 
well as to substrate variability [17, 19]. Moreover, some 
authors also suggested that in a routine context, the fre-
quent mixed homogeneous and speckled patterns or 
quasi-homogeneous patterns are difficult to distinguish 
from the characteristic DFS70 ANA-IIF pattern [27]. In 
addition, it has been postulated that there are likely also 
other antigen targets that produce a DFS IIF pattern. One 
target recently suggested was MeCP2 (methyl CpG protein 
2), but the presence of antibodies targeting this antigen 
could not be confirmed in human sera [28]. This variabil-
ity/difficulty was also observed in our study with differ-
ences observed between HEp-2 and HEp-2000 results as 
well as interreader variability (data not shown). To over-
come this, we did not use the criterion of the character-
istic DFS pattern for inclusion for further testing, but we 
applied the broader homogeneous-like criterion. The 
frequency of the homogeneous-like pattern within each 
cohort ranged between 3% and 19% (at titer 1:160). The 
higher frequency of homogeneous-like samples in one of 
the secondary care centers compared to tertiary care is 
in line with the higher frequency of requests originating 
from the rheumatology department.
We also compared anti-DFS70 data from different 
solid phase assays. Our results revealed a substantial 
agreement between CLIA (based on TC antigen) and the 
FL antigen assays (DFS70 ELISA or LB, both from the 
same manufacturer). However, it was remarkable that 
the discordant samples were mostly single positive with 
the FL antigen assays. Our observations are in line with 
the findings of Bizzaro and colleagues [20], who also 
identified more anti-DFS70 using Euroimmun assays 
compared to CLIA. Theoretically, this higher sensitivity 
of the FL antigen assays compared to TC antigen assays, 
could be related to targeted epitopes not included in the 
TC recombinant antigen. Nevertheless, their results sug-
gested that the differences in the assays are not reduc-
ible to differences in type of antigen used (TC vs. FL), as 
higher sensitivity compared to CLIA was also observed 
with another TC antigen assay. The same authors also 
suggested a possible impact of the applied cutoff for 
positivity. This was compatible with the results of our 
study, as most discordant samples showed low posi-
tivity in the FL assays (data not shown) and presence 
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of AARD-related ANA. In addition, we observed in an 
unselected consecutive cohort of routine samples (UZG, 
n = 186) that discordant anti-DFS70  samples (n = 8/9) 
did not show an isolated homogeneous-like pattern 
on ANA-IIF (data not shown). Within this context, we 
suggest not to report anti-DFS70 in absence of an iso-
lated homogeneous-like pattern.
Recent observations suggest that especially anti-
DFS70 in absence of other AARD-related ANA (referred to 
as ‘isolated anti-DFS70’) might contribute to explaining 
a significant proportion of these AARD-unrelated ANA-
IIF-positive results [7, 8]. Within this context, we would 
also like to highlight that the definition of isolated anti-
DFS70 differs between studies. We used in our study two 
approaches: (1) based on negative results in the routine 
anti-ENA/dsDNA assays and (2) based on the disappear-
ance of the DFS-pattern on IIF after immunoabsorption. 
The latter approach allows for a more narrow definition 
of isolated anti-DFS70 as also ANA-IIF-positive reactivities 
not included in the classical anti-ENA assays are detect-
able. In our study, co-occurrence of anti-DFS70  with 
routinely detected AARD-associated ANA was mostly 
observed in the FL DFS70-positive samples (overall 31%, 
up to 71% in the subset with single FL antigen reactivity). 
In the samples with CLIA DFS70 reactivity, co-occurrence 
with routinely detected AARD-associated ANA was lower 
(7%–20%), with the highest frequency observed in tertiary 
care. In these samples, the highest AARD-association was 
also observed (see also below). Globally, these observa-
tions suggest a higher specificity of DFS70 CLIA and high-
light the importance of focusing on the isolated presence 
of anti-DFS70.
Some authors suggested that the isolated presence 
of anti-DFS70 could be used as an exclusion marker for 
AARD, a suggestion based on the observation of lower 
prevalence of anti-DFS70 in AARD (median 3.9%) com-
pared to healthy persons (7.6%) [7]. This idea was also 
supported by the lower median prevalence of isolated 
anti-DFS70 in AARD patients (<1%) [7]. Nevertheless, in 
healthy donors, the coincidence of anti-DFS70 with ANA, 
and especially AARD-associated ANA, was not always 
thoroughly investigated [7]. We found between 0% and 
77% AARD association within our anti-DFS70-positive 
cohort (depending on the definition of anti-DFS70 positiv-
ity and cohort). Therefore, our data do not support that 
anti-DFS70 can exclude AARD. To our opinion, in a posi-
tive ANA IIF sample, it is rather the absence of a AARD-
related ANA and clinical symptoms that contributes in 
the exclusion of AARD than the presence of anti-DFS70. 
Nevertheless, we can agree that anti-DFS70 may explain 
positive ANA-IIF results, contributing in the clarification 
of diagnostic challenges.
Some authors claimed that measurements of anti-
DFS70 are cost-effective in patients with AARD suspi-
cion by comparing costs of follow-up laboratory testing 
and follow-up clinic visits after integration of anti-DFS70 
analysis in their workup algorithm [29]. They calculated 
a cost saving of laboratory costs of about 17,000 euros by 
applying their new algorithm. This was based on the pres-
ence of anti-DFS70 in 23 samples of a total of 170 ANA-IIF 
homogeneous or speckled positive samples (13%). Unfor-
tunately, details on the result calculations are not men-
tioned, but a decrease of 50% for anti-ENA and 75% for 
anti-dsDNA after implementation of their new approach 
is described. For comparison, we estimated a decrease of 
8%–21% in anti-ENA/dsDNA tests based on the assump-
tion that no testing will be performed during follow-up in 
case of isolated anti-DFS70 positivity. These differences 
emphasize on the importance of taking into account the 
care setting (or alternatively the referral pattern or origin 
of the requests) when performing cost-effectiveness 
studies.
Our study has some limitations. First, as this study 
followed out of the real routine laboratory situation, all 
centers used their established routine method for ANA-IIF 
and the detection of anti-ENA and anti-dsDNA. Therefore, 
we cannot exclude possible differences between centers 
in the definition of homogeneous-like samples as well as 
the definition of samples without AARD-associated ANA. 
Second, our study did not take into account possible dif-
ferences between the two methods using FL antigen as 
both methods were produced by the same manufacturer, 
and only one assay with truncated antigen was performed. 
Third, the clinical association study was limited to the sec-
ondary and tertiary care samples.
In conclusion, the anti-DFS70 prevalence depends on 
the applied assays and the care setting, with anti-DFS70 
CLIA positivity being most prevalent in primary care. Our 
data suggest that, in a patient with a positive ANA-IIF 
result, it is rather the absence of a AARD-associated ANA 
and clinical symptoms that contribute to the exclusion of 
AARD than the presence of anti-DFS70. Nevertheless, anti-
DFS70 in absence of AARD-associated ANA may contribute 
to the clarification of positive ANA-IIF results, especially 
if pretest probability for AARD is low. Cost-effectiveness 
studies are useful but should take into account the care 
setting/referral pattern/origin of the requests.
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